“With a potentially best-in-class bladder cancer therapy and two de-risked rare disease programs, Protara has the opportunity to meaningfully impact patient outcomes,” said Mr. Conkling.“I look ...

PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –  – ...